1072 Large-scale Validation Confirms Lack of Prognostic Impact of Aberrant p53 Status in POLEmut and MMRd Endometrial Carcinoma
No Thumbnail Available
Authors
Vermij L.
Huvila J.
Jamieson A.
McAlpine J.
Lueng S.
Jobsen J.
Smit V.
de Boer S.
Nout R.
Powell M.
Contact
Check for full-text access
Issue Date
2026
Type
Conference Proceedings
Language
Keywords
Alternative Title
Abstract
Background: A small but clinically relevant subset of endometrial carcinomas (EC) have more than one molecular classifying feature; e.g. a pathogenic POLE mutation as well as mismatch repair deficiency, and/or abnormal p53-expression. Prior studies suggest these patients with POLE-mutated (POLEmut) or mismatch repair deficient (MMRd) tumors that also have aberrant p53 expression, so-called "double classifiers", have clinical outcomes and genomic profiles more aligned with single-classifier POLEmut or MMRd tumors respectively. Using the largest collection of molecularly classified EC-cohorts to date, we evaluated whether aberrant p53 status affects outcome in such cases. Design(s): We analyzed tumor material from 12 international molecularly classified EC cohorts (retrospective, prospective, and randomized clinical trials; n=5958). Cases harboring a pathogenic TP53 mutation and/or aberrant p53 immunohistochemistry together with a pathogenic POLE mutation and/or MMR deficiency were included. Recurrence-free survival (RFS) was compared among patients with POLEmut-p53abn, MMRd-p53abn and POLEmut-MMRd-p53abn EC versus their respective single-classifier counterparts using Kaplan-Meier and log-rank tests. Result(s): We identified 164 (2.8%) double classifier EC, including 51 (31.1 %) POLEmut-p53abn EC, and 113 (68.9 %) MMRd-p53abn EC. The stage distribution was as follows; 120 stage I (73.2%), 17 stage II (10.4%), 22 stage III (13.4%), and 5 stage IV (3.0%). Five-year RFS (Figure 1A) did not differ between POLEmut-p53abn and POLEmut tumors (93.4% vs 96.8%; p = 0.48) or between MMRd-p53abn and MMRd tumors (78.1% vs 80.0%; p = 0.63). In contrast, single-classifier p53abn EC showed markedly worse 5-year RFS (52.6%). Subanalyses including only stage I cases (Figure 1B), for which molecular classification has a great impact on clinical management, also revealed no significant differences in five-year RFS between POLEmut-p53abn and POLEmut tumors (96.8% vs 97.3%; p = 0.78) or between MMRd-p53abn and MMRd tumors (87.2% vs 86.3%; p = 0.94). [Formula presented] [Formula presented] Conclusion(s): Aberrant p53 status does not impact prognosis in EC with pathogenic POLE mutations or MMR deficiency. These findings further support classifying POLEmut-p53abn as POLEmut EC, and MMRd-p53abn as MMRd EC. Copyright © 2025
Description
Citation
Publisher
License
Journal
Laboratory Investigation
Volume
Issue
SI: USCAP 115th Annual Meeting.